STERILE INJECTABLES MARKET ANALYSIS

Sterile Injectables Market, By Molecule Type (Large Molecules and Small Molecule), By Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, Peptide Antibiotics, and Others), By Disease Indication (Cancer, Diabetes, Cardiovascular Disorders, Musculoskeletal Disorders, CNS disorders, Infectious Disorders and Others), By Route of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On July 9, 2024 Amneal Pharmaceuticals, Inc. and Steriscience have jointly launched FOCINVEZ, a new injectable product. This ready-to-use fosaprepitant injectable differs from others on the market by being free of Polysorbate 80. It comes in a single-dose vial format that requires no reconstitution or dilution, facilitating direct administration with the included vial hanger.
In April 2023, Bridgewest Group, a renowned global private investment firm known for nurturing innovative enterprises in life sciences, software, and deep tech sectors, has finalized the acquisition of the Perth sterile injectable manufacturing facility from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. This acquisition follows Bridgewest Group's earlier announcement of a definitive agreement to purchase the facility late last year.
In November 2022, The U.S. FDA approved the combination of tremelimumab, durvalumab, and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults.
In May 2022, the U.S. FDA approved Eli Lilly's Mounjaro (tirzepatide) injection, a novel weekly treatment utilizing GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists to enhance blood sugar management in adults with type 2 diabetes.